Brooklyn ImmunoTherapeutics, Inc. (NYSE: BTX) is a clinical-stage biotechnology company dedicated to the development of next-generation cancer immunotherapies. The company’s core technology platform employs a multifaceted immunomodulatory approach—referred to as “MBTA” (Mannan-BAM, Toll-like receptor agonists, and anti-CD40 monoclonal antibody)—designed to stimulate both innate and adaptive immune responses against solid tumors. Its lead product candidate, BRTX-100, is currently being evaluated in early-stage clinical trials for safety, tolerability, and preliminary anti-tumor activity in patients with advanced cancers. Brooklyn ImmunoTherapeutics also maintains a robust preclinical pipeline targeting a range of tumor types and exploring combination therapies with existing immune checkpoint inhibitors.
Founded in 2017 and headquartered in Brooklyn, New York, the company operates research and manufacturing facilities in the greater New York metropolitan area and collaborates with academic institutions and contract research organizations across the United States and Europe. Its in-house team oversees all stages of drug development, from concept validation and formulation through to regulatory filings and clinical execution. Brooklyn ImmunoTherapeutics has secured investigational new drug (IND) clearances from the U.S. Food and Drug Administration and is preparing for expanded trials in selected international markets.
Under the leadership of co-founder and Chief Executive Officer Jonathan Zalevsky, Ph.D., the organization has assembled a management team with extensive experience in oncology drug development, commercial strategy, and regulatory affairs. Co-founder and Chief Scientific Officer Adi Bar-Lev, Ph.D., leads the ongoing refinement of the MBTA platform, guiding both translational research and process development efforts. The board of directors features industry veterans from leading biopharmaceutical companies and academic research centers, ensuring a strategic focus on rapid yet rigorous advancement of its novel immuno-oncology assets.
With a mission to transform treatment paradigms for patients with difficult-to-treat solid tumors, Brooklyn ImmunoTherapeutics continues to invest in its proprietary platform, strengthen its clinical development capabilities, and explore strategic partnerships. The company aims to deliver meaningful and durable therapeutic options that harness the body’s own defenses to combat cancer globally.
AI Generated. May Contain Errors.
